Bank of America Analysts Give Novartis (NOVN) a CHF 87 Price Target
Novartis (VTX:NOVN) has been given a CHF 87 price target by analysts at Bank of America in a research note issued on Wednesday. The brokerage presently has a “sell” rating on the stock. Bank of America’s price target indicates a potential upside of 5.71% from the stock’s previous close.
A number of other equities research analysts have also issued reports on the company. set a CHF 90 target price on Novartis and gave the company a “buy” rating in a research report on Tuesday, September 19th. Baader Bank set a CHF 90 target price on Novartis and gave the stock a “buy” rating in a research note on Monday, October 30th. Berenberg Bank set a CHF 88 target price on Novartis and gave the stock a “neutral” rating in a research note on Monday, October 30th. Sanford C. Bernstein set a CHF 97 price target on Novartis and gave the company a “buy” rating in a research note on Thursday, October 26th. Finally, Societe Generale set a CHF 95 price target on Novartis and gave the company a “buy” rating in a research note on Wednesday, October 25th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of CHF 86.41.
Novartis (VTX NOVN) opened at CHF 82.30 on Wednesday. Novartis has a 1-year low of CHF 67.85 and a 1-year high of CHF 85.40.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.